

Title of the study: **ADPedKD: An international web-based database for longitudinal data registry of children with Autosomal Dominant Polycystic Kidney Disease (ADPKD)**

Sponsor of the study: **UZ Leuven**

Research Institution: **UZ Leuven, Herestraat 49, 300 Leuven**

Medical Ethics Committee: **Ethische Commissie onderzoek UZ / KU Leuven**

Local investigators: Prof. Dr. Djalila Mekahli ([Djalila.mekahli@uzleuven.be](mailto:Djalila.mekahli@uzleuven.be))

Clinical trial assistant: Lotte Vanmeerbeek ([lotte.vanmeerbeek@uzleuven.be](mailto:lotte.vanmeerbeek@uzleuven.be))

Department of pediatric nephrology : U.Z. Leuven | Herestraat 49 - 3000 Leuven | Tel (016) 34 38 22

## **I Information vital to your decision to take part (4 pages)**

### **Introduction**

You are being invited to take part in an observational clinical study, because you are being followed up for the condition "Autosomal dominant polycystic kidney disease (ADPKD)". In this study, you will be asked to participate in the ADPKD patient registry, which is called ADPedKD. This means that the treatment you have been offered was prescribed in the usual manner, in accordance with the conditions of good medical practice and independently of your possible participation in this study. We are simply asking you whether we can collect data from your medical records to be able to combine them with those of other patients receiving the same treatment and to process them statistically for research purposes. No additional diagnostic or monitoring procedure will be proposed.

Before you agree to take part in this study, we invite you to take note of its implications in terms of organisation, possible risks and benefits, to allow you to make a decision with full awareness of the implications. This is known as giving "informed consent".

Please read these few pages of information carefully and ask any questions you want to the investigator or his/her representative.

There are 3 parts to this document: the information essential to your decision, your written consent and supplementary information (appendices) detailing certain aspects of the basic information.

### **If you take part in this study, you should be aware that:**

- The treatment offered to you by the investigator in accordance with current recommendations will not be altered if you take part in the study.
- This clinical study is being conducted after having been reviewed by one ethical committee.
- Your participation is voluntary and must remain free from any coercion. It requires the signature of a document expressing your consent. Even after having signed this document, you can stop taking part by informing the investigator.
- The data collected on this occasion are confidential and the protection of your identity is guaranteed during publication of the results.
- Insurance has been taken out in case you should suffer any damage in connection with your participation in this clinical study.
- You may contact the investigator or a member of his/her team at any time should you need any additional information.

Further information about your "Rights as a participant in a clinical study" can be found in appendix III.

## **Objectives and course of the study**

This clinical study has been organised to collect data from ADPKD patients from infancy around the world.

"Autosomal Dominant Polycystic Kidney Disease" (abbreviated as ADPKD) is the most common inherited kidney disease and responsible for nearly 10% of cases of kidney failure. Due to the development of cysts in the kidneys, kidney function is lost in half of the patients, on average by age 60. There is only one disease-specific treatment available for this condition and it can only inhibit the disease, often at the cost of significant side effects.

Knowledge of the cellular-level changes that occur in ADPKD is rapidly increasing. Several therapies are currently under study in animal models and/or adult ADPKD patients. However, the results have been disappointing and the remedies have many side effects.

The question we are asking is whether these products would work better if started at a younger age. By this we mean when there is still more normal kidney tissue. However there are still many question marks, currently there are no parameters to follow and predict the disease progression for children with ADPKD. In childhood we see proteinuria (increased amount of protein in the urine) in about 23% of patients and increased blood pressure in 5 to 44%, which may or may not result in thickening of the left ventricle. It is still unclear to what extent these disease features contribute to disease progression.

In addition it is important to emphasize that ADPKD is a disease that does not only affect the kidneys. Cysts can develop in other organs, most frequently at the level of the liver. In addition there is an increased risk of illness or death from cardiovascular disease in these patients. Patients with ADPKD are more likely to die from cardiovascular disease than from kidney disease.

This study aims to identify the symptoms and course of disease that may indicate mild or worse (from younger age) progression of the disease. Are there potentially patients who would benefit from early treatment? Which treatments have already been tried and which treatment showed good results? In addition, we are trying to find out the genetic causes of the observed variety of symptoms. Are there genetic variants that determine the progression of the disease? Special attention will also be given to the initial presentation of the disease, birth data, and follow-up of the disease.

We are inviting you to take part in this clinical study because because you are suffering from ADPKD. Any ADPKD patient who is followed up from infancy can participate in the registry. A member of your medical team can only include data if you have given your written consent. Please note that only physicians or other medical personnel (e.g. study nurse) can add data to the ADPeDKD. You cannot send data yourself. Patients with renal cysts due to other reasons than ADPKD cannot participate.

This clinical study is to include 2000 patients, including approximately 100 in Belgium.

Your participation in the study will last until the transition from paediatric to adult nephrology and is maximum until the age of 19 years. During this period, your physician-investigator will include available clinical data during the annual review, for example, symptoms, ultrasound results, lab results, family history, and genetic studies performed. In addition, annual follow-up data, for example regarding renal function or new symptoms that may have developed, will also be added to the database.

## **Description of risks and benefits**

As indicated above, neither the treatment that has been proposed nor the diagnostic and monitoring procedures for your clinical situation go beyond good medical practice. No risk, in terms of health, can be linked to your participation in this study.

Participation in this study does not guarantee any direct benefit to yourself. However, the knowledge gained from your participation may help patients with ADPKD in the future.

**Withdrawal of consent**

Your participation is voluntary and you are entitled to withdraw your consent to take part in the study for any reason, without having to justify your decision.

If you withdraw your consent to take part in the study, to guarantee the validity of the research, the data encoded up to the point at which you withdraw will be retained. No new data may be sent to the sponsor.

**If you take part in this study, we ask you:**

- To cooperate fully in the smooth running of this study.
- Not to conceal anything such as information relating to your state of health, the medication you are taking or the symptoms you are experiencing.
- To inform your doctor if you are asked to take part in another study to discuss with him/her the possibility of taking part in this study and to see whether you should then stop taking part in the present study.
- The possible need for investigator to contact the GP for the gathering of additional information when appropriate

**Contact**

If you need further information, but also if you have problems or concerns, you can contact the investigator prof. Djalila Mekahli or a member of his/her research team Vanmeerbeek Lotte on the following telephone number: 016/34.32.24

If you have any questions relating to your rights as a participant in a clinical study, you can contact the patient rights ombudsman of your institution on this telephone number: [+32 16 34 48 18](tel:+3216344818). If necessary, he/she can put you in contact with the ethics committee.

Title of the study: **ADPedKD: An international web-based database for longitudinal data registry of children with Autosomal Dominant Polycystic Kidney Disease (ADPKD)**

## **II Informed consent**

### **Participant**

I declare that I have been informed of the nature of the study, its purpose, its duration, the possible side effects and what is expected of me. I have taken note of the information document and the appendices to this document.

I have had sufficient time to think about it and discuss it with a person of my choice (GP, relative).

I have had the opportunity to ask any questions that came to mind and have obtained a favourable response to my questions.

I understand that my participation in this study is voluntary and that I am free to discontinue my participation in this study without harming my relationship with the therapeutic team responsible for my health.

I understand that data about me will be collected throughout my participation in this study and that the investigator and the sponsor of the study will guarantee the confidentiality of these data in accordance with applicable European and Belgian legislation. I understand that the performance of this study by UZ Leuven serves the general interest and that the processing of my personal data is necessary for the performance of this study.

### **I agree / I do not agree (delete as appropriate)**

that the study data collected for the study listed here will be processed later, provided that such processing is limited to the context of the study listed here for better knowledge of the disease and its treatment.

### **I agree / I do not agree (delete as appropriate)**

That my family doctor or other specialists concerned with my health be contacted about my participation in the study. And that, if necessary, they will be contacted additionally to obtain additional information about my health.

I have received a copy of the information to the participant and the informed consent form.

Name: .....

Birthdate: .....

Date: .....

Signature: .....

**Witness/Interpreter** [If a witness/interpreter is present.]

I was present during the entire process of informing the patient and I confirm that the information on the objectives and procedures of the study was adequately provided, that the participant (or his/her legal representative) apparently understood the study and that consent to participate in the study was freely given.

Name: .....

Function: .....

Signature: .....

Date: .....

**Investigator**

I, the undersigned, investigator or clinical research assistant, confirm that I have verbally provided the necessary information about the study and have given the participant a copy of the information document.

I confirm that no pressure was applied to persuade the patient to agree to take part in the study and that I am willing to answer any additional questions if required.

I confirm that I operate in accordance with the ethical principles set out in the latest version of the "Helsinki Declaration", the "Good Clinical Practices" and the Belgian Law of 7 May 2004 related to experiments on humans.

Name: .....

Function: .....

Signature: .....

Date: .....

Title of the study: **ADPedKD: An international web-based database for longitudinal data registry of children with Autosomal Dominant Polycystic Kidney Disease (ADPKD)**

### **III Supplementary information**

#### **1: Supplementary information on the organisation of the study**

We will recruit patients with ADPKD, from infancy onwards, both retrospectively and prospectively, initially from centers participating in the ARegPKD, which already includes 323 ARPKD patients, and from the ERKNet network. Here it is important to note that ADPKD is much more frequent compared to ARPKD: 1/400-1000 live births versus 1/20 000, respectively. The diagnosis of ADPKD is based on genetic analysis or a positive family history and imaging. After signing the informed consent, patient data are entered pseudonymously into the web-based database.

#### **2: Supplementary information on the protection and rights of the participant in a clinical study**

##### ***Ethics Committee***

This study has been reviewed by an independent Ethics Committee, namely the Ethics Committee of [Ethische Commissie Onderzoek UZ/KU Leuven](#), which has issued a favourable opinion. It is the task of the Ethics Committees to protect people who take part in a clinical trial. They make sure that your rights as a patient and as a participant in a clinical study are respected, that based on current knowledge, the study is scientifically relevant and ethical.

The Ethics Committees shall issue an opinion on these matters in accordance with Belgian law of May 7, 2004.

You should not under any circumstances take the favourable opinion of the Ethics Committee as an incentive to take part in this study.

##### ***Voluntary participation***

Before signing, do not hesitate to ask any questions you feel are appropriate. Take the time to discuss matters with a trusted person if you so wish.

Your participation in the study is voluntary and must remain free of any coercion: this means that you have the right not to take part in the study or to withdraw without giving a reason, even if you previously agreed to take part. Your decision will not affect your relationship with the investigator or the quality of your future therapeutic care.

If you agree to take part in this study, you will sign the informed consent form. The investigator will also sign this form to confirm that he/she has provided you with the necessary information about the study. You will receive a copy of the form.

##### ***Costs associated with your participation***

You will not be compensated for your participation in this study. However, your participation will not impose any additional costs on you.

##### ***Guarantee of confidentiality***

Your participation in the study means that your personal data are collected by the investigator and used in an encoded form by the study sponsor for research purposes and in connection with scientific and medical publications.

The processing of your personal data is necessary to achieve the scientific research purposes as set out herein. The conduct of scientific research is one of the core missions of UZ Leuven as defined by law. As a university hospital, part of KU Leuven, UZ Leuven is

indeed required to support research and education in the public interest. We would therefore like to inform you that the necessity of the processing for the conduct of scientific research as a task of public interest constitutes the lawful basis on which we process your information in the context of the study in which you are participating. UZ Leuven is also subject to specific legal requirements which require the processing of your personal in the context of safety reporting (such as for example the notification of adverse events to the regulatory authorities).

Your data will be processed in accordance with the European General Data Protection Regulation (GDPR). [UZ Leuven](#) shall act as data controller for your data.

You are entitled to ask the investigator what data are being collected about you and what is their use in connection with the study. This data concerns your current clinical situation but also some of your background, the results of examinations carried out within the context of care of your health in accordance with current standards. You have the right to inspect these data and correct them if they are incorrect<sup>1</sup>.

The investigator has a duty of confidentiality vis-à-vis the data collected.

This means that he/she undertakes not only never to reveal your name in the context of a publication or conference but also that he/she will encode your data before sending them to the manager of the database of collected data ([UZ Leuven](#)).

The investigator and his/her team will therefore be the only ones to be able to establish a link between the data transmitted throughout the study and your medical records<sup>2</sup>.

The personal data transmitted will not contain any combination of elements that might despite everything allow you to be identified<sup>3</sup>.

For the study data manager designated by the sponsor, the data transmitted will not allow you to be identified. The latter is responsible for collecting the data gathered by all investigators taking part in the study, processing them and protecting them in accordance with the requirements of the Belgian law on the protection of privacy.

To verify the quality of the study, it is possible that your medical records will be examined by third parties (ethics committee, representatives of the study sponsor, external auditors). In any event, this may only take place under the responsibility of the investigator or of one of his/her colleagues and by persons subject to the obligation of professional secrecy.

These (encoded) data will be able to be sent to Belgian or other regulatory authorities, to the relevant ethics committees, to other doctors and/or to organisations working in collaboration with the sponsor.

These doctors and/or organisations can be situated in Belgium and in other countries where the standards in terms of the protection of personal data may be different or less stringent<sup>4</sup>.

Your consent to take part in this study therefore also the use of your encoded medical data for the purposes described in this information form and to their transmission to the aforementioned people and authorities.

The sponsor will use the data collected within the context of the study in which you are taking part, but would also like to be able to use them in connection with other research concerning the same disease as yours and its treatment. Any use of your data outside the context described in this document is only possible with the approval of the ethics committee.

---

<sup>1</sup> These rights are guaranteed by the European Data Protection Regulation (GDPR) and by the Law of 22 August 2002 on patient rights.

<sup>2</sup> For clinical studies, the law requires this link with your records to be retained for 20 years.

<sup>3</sup> The database containing the results of the study will therefore not contain any combination of elements such as your initials, your gender and your full date of birth (dd/mm/yyyy).

<sup>4</sup> The sponsor then undertakes to respect the constraints of the European General Data Protection Regulation (GDPR) and the Belgian legislation on the protection of natural persons with regard to the processing of personal data.

If you withdraw your consent to take part in the study, to guarantee the validity of the research, the data encoded up to the point at which you withdraw will be retained. No new data may be sent to the sponsor.

If you have any questions relating to how your data are being processed, you may contact the investigator. The data protection officer in your hospital can be contacted as well: DPO - UZ Leuven, Herestraat 49, 3000 Leuven, e-mail [dpo@uzleuven.be](mailto:dpo@uzleuven.be).

Finally, if you have a complaint concerning the processing of your data, you can contact the Belgian supervisory authority who ensures that privacy is respected when personal data are processed.

The Belgian supervisory authority is called:  
Data Protection Authority (DPA)  
Drukpersstraat 35,  
1000 Brussels  
Tel. +32 2 274 48 00  
e-mail: [contact@apd-gba.be](mailto:contact@apd-gba.be)  
Website: <https://www.dataprotectionauthority.be>

### ***Insurance***

In an observational study, the only possible risk would be a flaw in the measures taken to protect the confidentiality of the private information about you. Even without fault, the sponsor accepts responsibility for damage caused to the participant (or his/her dependants) and linked directly or indirectly to participation in this study. In this context, the sponsor has taken out an insurance contract (Amlin Corporate Insurance, polisnr. 299.053.700, contact details insurance broker: Vanbreda Risk & Benefits, Plantin en Moretuslei 297, 2140 Antwerpen)<sup>5</sup>.

---

<sup>5</sup> In accordance with Article 29 of the Belgian Law related to experiments on humans (7 May 2004)